Calendar of Events
M Mon
T Tue
W Wed
T Thu
F Fri
S Sat
S Sun
1 event,
Pearls and Common Challenges for the Diagnosis of Bullous Pemphigoid (BP)
by Timothy Patton, DO
Pearls and Common Challenges for the Diagnosis of Bullous Pemphigoid (BP)
by Timothy Patton, DO
Learn more about the diagnosis and assessment of bullous pemphigoid (BP) including clinical manifestations, key laboratory investigations for diagnostic evaluation, consensus-based recommendations and a treatment option for appropriate BP patients
1 event,
DUPIXENT®(dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Roopen Patel, MD
DUPIXENT®(dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Roopen Patel, MD
Join us for a virtual discussion with an expert speaker and an adult patient with atopic dermatitis (AD) to Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation
2 events,
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Douglas DiRuggiero, PA-C
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Douglas DiRuggiero, PA-C
This program is being held in partnership with SDPA. Please visit the link below to be taken to the registration page for this program. Register
Beneath the Itch: The Role of Type 2 Inflammation and a Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Ben Ehst, MD
Beneath the Itch: The Role of Type 2 Inflammation and a Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Ben Ehst, MD
Learn more about itch in patients with atopic dermatitis (AD), prurigo nodularis (PN), and chronic spontaneous urticaria (CSU) and a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation
1 event,
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Marc Serota, MD
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Marc Serota, MD
Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation
0 events,
0 events,
0 events,
2 events,
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Karan Lal, DO
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Karan Lal, DO
This program is being held in partnership with SDPA. Please visit the link below to be taken to the registration page for this program. Register
DUPIXENT@ (dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Omar Noor, MD
DUPIXENT@ (dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Omar Noor, MD
Join us for a virtual discussion with an expert speaker and an adult patient with prurigo nodularis (PN) to Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation
1 event,
Clinical Case Discussion: A Pediatric Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age
by Autumn Burnette, MD
Clinical Case Discussion: A Pediatric Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age
by Autumn Burnette, MD
Join us for a program discussing a real-world case of a pediatric patient with moderate-to-severe atopic dermatitis (AD) and a treatment option that may help appropriate patients with Type 2 inflammation
0 events,
2 events,
Clinical Case Discussion: An Adolescent Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age
by Amy Spizuoco, DO
Clinical Case Discussion: An Adolescent Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age
by Amy Spizuoco, DO
Join us for a program discussing a real-world case of an adolescent patient with moderate-to-severe atopic dermatitis (AD) and a treatment option that may help appropriate patients with Type 2 inflammation
Pearls and Common Challenges for the Diagnosis of Bullous Pemphigoid (BP)
by Daniel Butler, MD
Pearls and Common Challenges for the Diagnosis of Bullous Pemphigoid (BP)
by Daniel Butler, MD
Learn more about the diagnosis and assessment of bullous pemphigoid (BP) including clinical manifestations, key laboratory investigations for diagnostic evaluation, consensus-based recommendations and a treatment option for appropriate BP patients
0 events,
0 events,
0 events,
2 events,
Diagnosing and Assessing Chronic Spontaneous Urticaria (CSU) and a Treatment Option for Appropriate CSU Patients 12+ Years of Age
by Leigh Ann Pansch, NP
Diagnosing and Assessing Chronic Spontaneous Urticaria (CSU) and a Treatment Option for Appropriate CSU Patients 12+ Years of Age
by Leigh Ann Pansch, NP
Learn more about the diagnosis and assessment of chronic spontaneous urticaria (CSU), including its clinical manifestations, diagnostic evaluation, assessment scales, and a treatment option for appropriate CSU patients 12+ years of age
DUPIXENT@ (dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Lakshi Aldredge, NP
DUPIXENT@ (dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Lakshi Aldredge, NP
Join us for a virtual discussion with an expert speaker and an adult patient with atopic dermatitis (AD) to Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation
0 events,
2 events,
DUPIXENT@(dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Sandri Johnson, NP
DUPIXENT@(dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Sandri Johnson, NP
Join us for a virtual discussion with an expert speaker and an adult patient with prurigo nodularis (PN) to Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation
Clinical Case Discussion: A Pediatric Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age
by Brittany Craiglow, MD
Clinical Case Discussion: A Pediatric Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age
by Brittany Craiglow, MD
Join us for a program discussing a real-world case of a pediatric patient with moderate-to-severe atopic dermatitis (AD) and a treatment option that may help appropriate patients with Type 2 inflammation.
2 events,
Clinical Case Discussion: An Adult Patient with Prurigo Nodularis and a Treatment Option for Appropriate Patients 18+ Years of Age
by Melissa Costner, MD
Clinical Case Discussion: An Adult Patient with Prurigo Nodularis and a Treatment Option for Appropriate Patients 18+ Years of Age
by Melissa Costner, MD
Join us for a program discussing a real-world case of an adult patient with prurigo nodularis (PN) and a treatment option that may help appropriate patients.
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Raffi Tachdjian, MD
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Raffi Tachdjian, MD
Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation